Cysteine proteinases and their inhibitors in the development of mouse HA-1 hepatoma and antineoplastic therapy

Undefined
6
Average: 6 (1 vote)
Biomed Khim. 2004 Mar-Apr;50(2):172-9. [Cysteine proteinases and their inhibitors in the development of mouse HA-1 hepatoma and antineoplastic therapy] [Article in Russian] Poteriaeva ON, Korolenko TA, Svechnikova IG, Zhanaeva SIa, Falameeva OV, Kaledin VI, Nowicky JW. Institute of Physiology RAMS, Institute of Biochemistry RAMS, Novosibirsk. Development of murine HA-1 [url=url=http://en.wikipedia.org/wiki/hepatoma]hepatoma[/url] was accompanied by increased activity of [url=http://en.wikipedia.org/wiki/Cathepsin_B]cathepsin B[/url] (in ascitic cells), [url=http://en.wikipedia.org/wiki/Cathepsin_D]cathepsin D[/url] (in ascitic fluid) and increased activity of procathepsin B. There were some changes of cysteine proteinases in liver and spleen, not involved directly into tumor growth. The most prominent changes included the decreased level of cysteine proteinase inhibitors cystatin C and stefin A in ascitic cells (and to a lesser degree in liver tissue). During tumor development serum cystatin C concentration decreased by 3-times compared to intact mice. Treatment by antitumor drug Ukraine increased life span of mice with HA-1 hepatoma (transplanted intravenously), decreased the increment of tumor weight. In ascite such treatment caused a decrease of number of tumor cells and an increase of number of macrophages. Ukraie (administered once or 5-times in a dose of 0.5 mg per mice) increased [url=http://en.wikipedia.org/wiki/Cystatin_C]cystatin C[/url] level, revealing protective mechanism of action.